News stories about Dipexium Pharmaceuticals (NASDAQ:PLXP) have trended somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dipexium Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.5040802532273 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Zacks: Analysts Set $12.00 Target Price for Dipexium Pharmaceuticals, Inc. (PLXP) (americanbankingnews.com)
- PLx Pharma Inc. Reports Third Quarter 2017 Results (finance.yahoo.com)
- PLx Pharma reports 3Q loss (finance.yahoo.com)
- PLx Pharma, Inc. to Host Earnings Call (finance.yahoo.com)
Shares of Dipexium Pharmaceuticals (NASDAQ PLXP) traded down $0.10 during midday trading on Tuesday, reaching $6.55. 12,500 shares of the company were exchanged, compared to its average volume of 14,633. Dipexium Pharmaceuticals has a 1 year low of $5.60 and a 1 year high of $22.00. The company has a current ratio of 8.99, a quick ratio of 8.88 and a debt-to-equity ratio of 0.56.
PLXP has been the subject of a number of recent research reports. UBS AG raised shares of Dipexium Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $12.00 price objective for the company in a research note on Monday, July 31st. Redburn Partners upgraded shares of Dipexium Pharmaceuticals to an “outperform” rating in a research report on Tuesday, August 1st. Finally, Zacks Investment Research lowered shares of Dipexium Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 19th.
ILLEGAL ACTIVITY WARNING: This story was first reported by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/11/15/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-dipexium-pharmaceuticals-plxp-stock-price.html.
About Dipexium Pharmaceuticals
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.